TS1723789936	sideeffect 59 84	myelodysplastic syndromes
TS2323789936	drug 91 124	multi-kinase inhibitor rigosertib
TS123789936	drugEffect 149 163	mitotic arrest
TS2023789936	drugEffect 168 192	apoptosis in myeloblasts
TS1823789936	treatedDisease 415 440	myelodysplastic syndromes
TS1423789936	drugEffect 779 794	bioavailability
TS1023789936	mealTime 825 828	fed
TS2223789936	mealTime 852 859	fasting
TS1123789936	sideeffect 935 943	toxicity
TS723789936	sideeffect 954 961	dysuria
TS823789936	sideeffect 966 985	shortness of breath
TS523789936	sideeffect 1053 1088	grade 3 non-haematological toxicity
TS623789936	sideeffect 1113 1136	urothelial inflammation
TS223789936	sideeffect 1139 1150	hypotension
TS923789936	sideeffect 1155 1162	syncope
TS1323789936	sideeffect 1165 1172	fatigue
TS423789936	sideeffect 1177 1191	abdominal pain
TS2123789936	drugEffect 1267 1277	remissions
TS1923789936	treatedDisease 1281 1299	refractory anaemia
TS1223789936	drug 1359 1370	azacitidine
T1	drug 31 41	rigosertib
R2	has_effect Arg1:TS2323789936 Arg2:TS123789936	
R3	has_effect Arg1:TS2323789936 Arg2:TS2023789936	
T2	drug 387 397	rigosertib
T3	modeadm 367 371	oral
T4	treatedDisease 443 446	MDS
R4	treat Arg1:T2 Arg2:TS1823789936	
T5	frequency 531 537	weekly
T6	drug 499 509	rigosertib
T7	drug 614 624	rigosertib
T8	frequency 625 636	twice daily
T9	duration 637 661	for 14 d of a 21-d cycle
T10	numbers 674 676	37
T11	drug 701 711	Rigosertib
T12	modeadm 747 751	oral
T13	dosage 892 898	560 mg
T14	frequency 899 905	b.i.d.
T15	dosage 1004 1010	700 mg
T16	frequency 1011 1016	b.i.d
T17	numbers 1027 1040	Five patients
T18	drugEffect 1415 1439	transfusion independence
T19	drugEffect 1444 1471	haematological improvements
T20	drug 1495 1505	rigosertib
T21	treatedDisease 1586 1589	MDS
T22	drugEffect 1551 1568	clinical activity
R1	treat Arg1:T20 Arg2:T21	
